Literature DB >> 23990206

T-cell immunoglobulin and mucin domain 3 acts as a negative regulator of atherosclerosis.

Amanda C Foks1, Ingrid A Ran, Loes Wasserman, Vanessa Frodermann, Mariëtte N D Ter Borg, Saskia C A de Jager, Peter J van Santbrink, Hideo Yagita, Hisaya Akiba, Ilze Bot, Johan Kuiper, Gijs H M van Puijvelde.   

Abstract

OBJECTIVE: Atherosclerosis is a chronic autoimmune-like disease in which lipids and fibrous elements accumulate in the arterial blood vessels. T cells are present within atherosclerotic plaques, and their activation is partially dependent on costimulatory signals, which can either provide positive or negative signals that promote T-cell activation or limit T-cell responses, respectively. T-cell immunoglobulin and mucin domain 3 (Tim-3) is a coinhibitory type 1 transmembrane protein that affects the function of several immune cells involved in atherosclerosis, such as monocytes, macrophages, effector T cells, and regulatory T cells. In the present study, we determined the role of Tim-3 in the development of atherosclerosis. APPROACH AND
RESULTS: Western-type diet-fed low-density lipoprotein receptor-deficient (LDLr(-/-)) mice were treated with an anti-Tim-3 antibody for 3 and 8 weeks. Anti-Tim-3 administration increased fatty streak formation with 66% and increased atherosclerotic plaque formation after 8 weeks with 35% in the aortic root and with 50% in the aortic arch. Furthermore, blockade of Tim-3 signaling increased percentages of circulating monocytes with 33% and lesional macrophages with 20%. In addition, anti-Tim-3 administration increased CD4(+) T cells with 17%, enhanced their activation status, and reduced percentages of regulatory T cells with 18% and regulatory B cells with 37%.
CONCLUSIONS: It is known that Tim-3 acts as a negative regulator of both innate and adaptive immune responses, and in the present study, we show that anti-Tim-3 treatment augments lesion development, accompanied by an increase in the number of monocytes/macrophages and CD4(+) T cells and by decreased regulatory T cells and regulatory B cells.

Entities:  

Keywords:  T cells; Tim-3; atherosclerosis; immunology; inflammation

Mesh:

Substances:

Year:  2013        PMID: 23990206     DOI: 10.1161/ATVBAHA.113.301879

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  19 in total

Review 1.  Lymphocytes in atherosclerosis.

Authors:  Catherine C Hedrick
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-02       Impact factor: 8.311

Review 2.  Immune Checkpoint Therapies and Atherosclerosis: Mechanisms and Clinical Implications: JACC State-of-the-Art Review.

Authors:  Jacqueline T Vuong; Ashley F Stein-Merlob; Arash Nayeri; Tamer Sallam; Tomas G Neilan; Eric H Yang
Journal:  J Am Coll Cardiol       Date:  2022-02-15       Impact factor: 24.094

3.  Increased Level of Tim-3+PD-1+CD4+T Cells With Altered Function Might Be Associated With Lower Extremity Arteriosclerosis Obliterans.

Authors:  Liyuan Cui; Lanting Chen; Yuxin Dai; JingMin Ou; Mingke Qiu; Songcun Wang
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

Review 4.  Regulation of T cell responses by the receptor molecule Tim-3.

Authors:  Jacob V Gorman; John D Colgan
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

5.  Blockade of Tim-1 and Tim-4 Enhances Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice.

Authors:  Amanda C Foks; Daniel Engelbertsen; Felicia Kuperwaser; Noah Alberts-Grill; Ayelet Gonen; Joseph L Witztum; James Lederer; Petr Jarolim; Rosemarie H DeKruyff; Gordon J Freeman; Andrew H Lichtman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-01-28       Impact factor: 8.311

Review 6.  Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis.

Authors:  A C Foks; J Kuiper
Journal:  Br J Pharmacol       Date:  2017-05-04       Impact factor: 8.739

Review 7.  Novel human immunomodulatory T cell receptors and their double-edged potential in autoimmunity, cardiovascular disease and cancer.

Authors:  Pilar Martín; Rafael Blanco-Domínguez; Raquel Sánchez-Díaz
Journal:  Cell Mol Immunol       Date:  2020-11-24       Impact factor: 11.530

8.  PD-1 and Tim-3 Pathways Regulate CD8+ T Cells Function in Atherosclerosis.

Authors:  Ming-Ke Qiu; Song-Cun Wang; Yu-Xin Dai; Shu-Qing Wang; Jing-Min Ou; Zhi-Wei Quan
Journal:  PLoS One       Date:  2015-06-02       Impact factor: 3.240

9.  Expression Level and Significance of Tim-3 in CD4+ T Lymphocytes in Peripheral Blood of Patients with Coronary Heart Disease.

Authors:  Jian Zhang; Feng Zhan; Huiling Liu
Journal:  Braz J Cardiovasc Surg       Date:  2022-05-23

10.  Serum Galectin-9 Levels Are Associated with Coronary Artery Disease in Chinese Individuals.

Authors:  Ruirui Zhu; Cheng Liu; Hongxia Tang; Qiutang Zeng; Xiang Wang; Zhengfeng Zhu; Yuzhou Liu; Xiaobo Mao; Yucheng Zhong
Journal:  Mediators Inflamm       Date:  2015-11-18       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.